MedTrace Logo

Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

NCT00116220 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2022-01-06

No results posted yet for this study

Summary

This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.

Conditions

Interventions

DRUG

Flutamide (Eulexin) and Lupron or Zoladex

Androgen suppression therapy

RADIATION

External Beam Radiotherapy

Once a day, 4-5 days per week for approximately 2 months

Sponsors & Collaborators

Principal Investigators

  • Anthony V D'Amico, M.D. Ph.D. · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
41 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-09-30
Primary Completion
2001-04-30
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116220 on ClinicalTrials.gov